ReviewCureus2025
Dapagliflozin and Anemia Outcomes: A Systematic Review and Meta-Analysis of Effects on Hemoglobin Levels, Anemia Correction, and Incidence in Patients With and Without Heart Failure.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review and meta-analysis evaluated the impact of dapagliflozin on anemia outcomes across different patient populations. A comprehensive literature search was conducted across multiple databases from inception to September 2025, identifying studies that reported anemia-related outcomes in adult patients receiving dapagliflozin treatment. Seven studies comprising 15,540 participants were included, encompassing randomized controlled trials and observational studies conducted across diverse geographical regions. All studies evaluated 10 mg of dapagliflozin once daily with a minimum four-week follow-up duration. The pooled analysis demonstrated significant improvements in hemoglobin levels with dapagliflozin compared to control groups (standardized mean difference [SMD]: 0.62; 95% CI: 0.43-0.80). Dapagliflozin treatment was associated with an 83% higher likelihood of anemia correction (relative risk: 1.83; 95% CI: 1.47-2.26) and a 78% reduction in anemia incidence (relative risk: 0.22; 95% CI: 0.08-0.60). Subgroup analyses revealed consistent benefits across all studied populations, with the most pronounced effects observed in heart failure patients (SMD: 0.78; 95% CI: 0.44-1.12), followed by chronic kidney disease (0.66; 95% CI: 0.36-0.95) and diabetes patients (0.45; 95% CI: 0.38-0.51). These findings suggest that dapagliflozin's therapeutic benefits extend beyond cardiovascular and renal protection to include meaningful improvements in anemia outcomes across multiple chronic disease states, potentially reducing healthcare burden and improving patient quality of life.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.